Phoenix Molecular Designs Appoints Magda Marquet, Ph.D. to its Board of Directors

March 22, 2019
Phoenix MD

VANCOUVER, British Columbia and SAN DIEGO, March 21, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today the appointment of Magda Marquet, Ph.D., to its Board of Directors. Dr. Marquet brings a wealth of entrepreneurial and biotech experience to PhoenixMD, having founded, led, and commercialized many highly successful companies, … Continue reading Phoenix Molecular Designs Appoints Magda Marquet, Ph.D. to its Board of Directors

TRIUMF receives historic investment in 2019 federal budget

March 20, 2019
TRIUMF Innovations

March 19, 2019, VANCOUVER, BC – Today, the Government of Canada reaffirmed its longstanding support for TRIUMF with the announcement of a $292.7M investment over five years to support laboratory operations. This funding represents the largest single investment in TRIUMF to date. It comes in response to the bold vision presented in TRIUMF’s recently publishedFive-Year Plan 2020-2025. Details of the new funding were included in the 2019 federal budget, which was … Continue reading TRIUMF receives historic investment in 2019 federal budget

New Scientific Study Finds Stevia Sweeteners Have No Impact on Digestive System Bacteria

March 14, 2019
Biopharmaceutical Research Inc. (BRI)

Chicago, Illinois March 4, 2019 – PureCircle, in collaboration with Biopharmaceutical Research Inc. (BRI), announces the results of important new scientific research which found that the company’s new generation stevia leaf sweeteners such as Reb D and Reb M have no impact on the system of bacteria in the human digestive system; that bacteria system … Continue reading New Scientific Study Finds Stevia Sweeteners Have No Impact on Digestive System Bacteria

Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives

March 7, 2019
Arbutus Biopharma Corp.

– Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg – Ongoing analyses of AB-452, a novel orally-available RNA destabilizer, with a go/no go decision expected in the second half of the year – Ongoing characterization of the RNA destabilizer mechanism and several novel compounds in … Continue reading Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives

Onestep Laboratories to develop a stable formula for Chlorine Analysis

Onestep Laboratories

Vancouver, BC – March 6, 2019 – Onestep Laboratories, a B.C. based biotech company that specializes in developing and producing raw material for immunoassay and other assays, has successfully developed a stable formula for chlorine analysis. Chlorine has been used for public health for more than a century. Today, more than 80,000 tons of chlorine … Continue reading Onestep Laboratories to develop a stable formula for Chlorine Analysis

Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update

March 6, 2019
XENON PHARMACEUTICALS INC.

Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Global XEN1101 Phase 2b Clinical Trial Underway with Data Anticipated in Second Half of 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 06, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, … Continue reading Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update

Arbutus to Present at Cowen Health Care Conference

March 4, 2019
Arbutus Biopharma Corp.

WARMINSTER, Pa., March 04, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark Murray, Arbutus’ President and CEO, will present a corporate overview and business update at the Cowen Health Care Conference on Monday, March 11, 2019 at 2:50 PM ESTin Boston. A live webcast of the presentation can be accessed through … Continue reading Arbutus to Present at Cowen Health Care Conference

Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update

February 28, 2019
Arbutus Biopharma

WARMINSTER, Pa., Feb. 28, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcast, for Thursday, March 7, 2019.  The schedule for the press release and conference call/webcast are … Continue reading Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update

February 27, 2019
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Feb. 27, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2018 financial and operating results after the close of U.S. financial markets on Wednesday, March 6, 2019.  Xenon management will host a conference call and live audio webcast at 4:30 pm … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update

Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

February 26, 2019
Xenon Pharmaceuticals Inc.

Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure SAN FRANCISCO, Feb. 26, 2019 (GLOBE NEWSWIRE) — As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions, BioMarin … Continue reading Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures